NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON

No dose-limiting toxicities were observed among 12 patients with advanced EGFR-mutated NSCLC treated with quaratusugene ozeplasmid and osimertinib.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

The EGFR/HER3 bispecific ADC is being evaluated in an open-label phase 1/2 study to assess its safety, tolerability, and activity in advanced solid tumors.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.